GlassScriptPhysician profile
Silaja Yitta
NPI 1437353067
$361.66
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $68.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.65 | 2019 | |
| Hologic INC | $31.84 | 2019-2020 | |
| Ge Healthcare | $29.51 | 2020 | |
| Amgen INC. | $29.15 | 2019 | |
| Blueprint Medicines Corporation | $24.97 | 2020 | |
| Incyte Corporation | $22.23 | 2019 | |
| Lunit Americas, INC. | $21.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.55 | 2019 | |
| Celgene Corporation | $16.35 | 2019 | |
| Eisai INC. | $16.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silaja Yitta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.